OSE Immunotherapeutics has signed a term sheet for a proposed flexible bridge equity financing with IRIS Capital Investment, with definitive signing expected in the coming days. Under the proposed facility, IRIS would be able to subscribe for up to 4m new ordinary shares over a 24-month period, rep
